An interventional study of Urine sampling and Blood sampling in Chronic Renal Failure, sponsored by Brugmann University Hospital. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-04.
Sponsored by Brugmann University Hospital · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Kidney Failure, Chronic with a site in Belgium — 8 open to participants now, 14 under way, 3 of them phase 3. Kidney Failure, Chronic · Belgium.
Among the 62 studies in Kidney Failure, Chronic with a site in Belgium, this one is the 12th largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 with no phase, reaches primary completion later than 2 of the 13 other live ones, and was the 56th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →8 of the 62 studies in Kidney Failure, Chronic with a site in Belgium are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Belgium
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
CSL Behring · Sites in Belgium, United States, Argentina and 32 more countries
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium, Netherlands
Ages 18+
Hamad Medical Corporation · Sites in Belgium
Ages 19+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 10 · Phase 4 5
First in 1994; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 71 across the 45 interventional studies, 150 across the 17 observational. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 62 have an industry lead sponsor. The 10 most frequent:
Brugmann University Hospital is the lead sponsor of 119 studies on the registry; 17 are open to participants now.
Brugmann University Hospital has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
2 of the studies in Kidney Failure, Chronic with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT07759167Regeneron PharmaceuticalsStudy of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | 2027-04-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Kidney Failure, Chronic with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The vascular endothelium is an organ in its own right, playing, among other things, a primordial role in the control of vascular tone. This vascular tone is ensured by pro-dilator mediators (nitric oxide (NO), prostacyclins (PGI2)), or vasoconstrictors (endothelin, thromboxane A2 or PGH2).Uremic toxin accumulation in chronic kidney disease (CKD) is a well-known factor in endothelial dysfunction, often associated with higher cardiovascular risk. This association is also present for terminal chronic kidney disease characterized by the need to resort to an extra-renal purification technique (in-center hemodialysis (HD), daily home hemodialysis (HDQ), peritoneal dialysis) or to resort to renal transplantation.
For HD to be effective, it is essential that the blood flow rate passing through the dialyzer is greater than 300ml/min. This imperative requires that any hemodialysis patient have specific vascular access (dialysis catheter or arteriovenous fistula (AVF)) to ensure these flow rates. The vascular access of choice is the arteriovenous fistula , because it is associated with a lower risk of infection and lower morbidity and mortality. Making an arteriovenous fistula consists of surgically creating an anastomosis between a vein and an artery.
Complications of arteriovenous fistula are common. Arteriovenous fistula maturation may be delayed (maturation delay) or even absent. Drainage veins and/or anastomoses can also be the site of stenosis or thrombosis. The pathophysiology of these complications is complex and multifactorial. Among the risk factors for these complications (delay or absence of maturation, stenosis thrombosis), the positivity of antiphospholipid antibodies (aPL) can be cited, as well as endothelial dysfunction.
Antiphospholipid syndrome (APS) is an autoimmune disease causing a thrombotic phenotype. This is an acquired thrombophilia. In the general population, the prevalence of antiphospholipid antibodies is around 0.5%; this prevalence is far from rare in hemodialysis, since it represents up to 37% in dialysis patients. In a retrospective study carried out at Brugmann University Hospital in 2023 , on 115 patients with AVF and in whom aPL dosages were available, the prevalence of persistent positivity (2 positive dosages spaced more than 12 weeks apart) was 21%.
Interestingly, a third of the cohort presented an antibody profile that did not allow them to be classified according to the classification criteria in force. This group corresponds to patients with a single positive dosage, either not recontrolled or recontrolled negative. This group was called Fluctuating. This fluctuating group was associated with arteriovenous fistula complications in a 2019 study.
Endothelial dysfunction is also implicated in the pathophysiology of APS. In clinical practice, the "flow mediated dilation" (FMD) test makes it possible to assess endothelial dysfunction in vivo. It involves the phenomenon of post-occlusive hyperemia which is mainly linked to NO and endothelium-dependent vasodilation. In the brachial artery, NO is the sole mediator of FMD. Endothelial dysfunction according to FMD has been described in populations with advanced chronic kidney disease, as well as patients with cardiovascular diseases. Hemodialysis patients with delayed/absence of arteriovenous fistula maturation have more pathological FMDs compared to dialysis patients without fistula problems. However, the additive role of aPL in this different population has not been studied in terms of endothelial dysfunction by FMD.
The objective of this study is to evaluate the weight of antiphospholipid biology on endothelial dysfunction in hemodialysis patients, using the FMD test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 60 and 45 ml/min/1.73m²
Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test
Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 45 and 30 ml/min/1.73m²
Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test
Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) between 30 and 15 ml/min/1.73m²
Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test
Renal clearance according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) less than 15 ml/min/1.73m² but not dialyzed
Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test
Patients who undergo dialyze
Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test
Healthy volunteer patient, without existing kidney disease
Procedure: Urine sampling · Procedure: Blood sampling · Device: Flow mediated dilatation test
Urine sampling
Blood sampling
The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
Nitric oxide (NO) plasma level
Nitric oxide (NO) plasma level
Time frame: pre-intervention
Endothelin 1 (ET-1) plasma level
Endothelin 1 (ET-1) plasma level
Time frame: pre-intervention
E-Selectine plasma level
E-Selectine plasma level
Time frame: pre-intervention
P-Selectine plasma level
P-Selectine plasma level
Time frame: pre-intervention
Intercellular Adhesion Molecule 1 (ICAM-1) plasma level
Intercellular Adhesion Molecule 1 (ICAM-1) plasma level
Time frame: pre-intervention
Interleukin 6 (IL-6) plasma level
Interleukin 6 (IL-6) plasma level
Time frame: pre-intervention
Nitric oxide (NO) urine concentration
Nitric oxide (NO) urine concentration
Time frame: pre-intervention
Endothelin 1 (ET-1) urine concentration
Endothelin 1 (ET-1) urine concentration
Time frame: pre-intervention
Tumour Necrosis Factor alpha (TNF alpha) urine concentration
Tumour Necrosis Factor alpha (TNF alpha) urine concentration
Time frame: pre-intervention
Interleukin 6 (IL-6) urine concentration
Interleukin 6 (IL-6) urine concentration
Time frame: pre-intervention
Flow mediated dilatation test result (%)
Flow-mediated dilation (FMD) is a non-invasive vascular function test that measures the change in artery diameter in response to reactive hyperemia. The result of the test is expressed as a percentage.
Time frame: pre-intervention
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 14 months is below that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brugmann University Hospital →